-
-
-
-
-
American College of Rheumatology (ACR) and Food and Drug Administration (FDA) Summit: Summary of the Meeting May 17-18, 2022 Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-15 Jonathan Kay, Nikolay P. Nikolov, Michael H. Weisman
On May 17-18, 2022, the ACR and the FDA co-sponsored a public meeting to address topics of mutual interest and importance in assessing long-term safety and clinical efficacy, as well as novel approaches to clinical trials in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). During the two-day consensus-building summit, rheumatologists, other health care professionals, and FDA staff provided
-
The unique interplay between antinuclear antibodies and nuclear molecules in the pathogenesis of SLE Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-16 David S. Pisetsky
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that primarily affects young women and causes a wide range of inflammatory manifestations. The hallmark of SLE is the production of antibodies to components of the cell nucleus (antinuclear antibodies or ANAs). These antibodies can bind to DNA, RNA and protein complexes with nucleic acids. Among ANAs, antibodies to DNA (anti‐DNA)
-
A GITRL‐mTORC1‐GM‐CSF positive loop promotes pathogenic Th17 response in exacerbating Primary Sjögren's Syndrome Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-09 Yuzhou Gan, Haotian Zhou, Yixue Guo, Bo Huang, Hongjiang Liu, Ziye Wang, Zijun Li, Xiaozhen Zhao, Huaqun Zhu, Qimao Han, Hua Ye, Jing He, Qingwen Wang, Zhanguo Li, Xiaolin Sun
sObjectivesGlucocorticoid‐induced Tumor‐Necrosis‐Factor‐Receptor Family‐related Protein (GITR), with its ligand (GITRL), plays an important role in CD4+T‐cell‐mediated autoimmunity. This study aimed to investigate the underlying mechanisms of GITRL in primary Sjögren's Syndrome (pSS).MethodspSS patients and healthy controls were recruited. Serum GITRL and Th17‐related cytokines were determinated. RNA‐Sequencing
-
EphB2 receptor promotes dermal fibrosis in systemic sclerosis Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-09 Erika SA Egal, Severin Donald Kamdem, Masaaki Yoshigi, Ching‐Chu Yang, Sarah Pellizzari, Ernest M Kameni, My N Helms, Shervin Assassi, Mark Henkemeyer, Tracy M Frech, Patrice N Mimche
ObjectivesEph/Ephrin cell‐cell signaling is emerging as a key player in tissue fibrogenesis. The aim of this study was to test the hypothesis that the receptor tyrosine kinase EphB2 mediates dermal fibrosis in systemic sclerosis (SSc).MethodsWe assessed normal and SSc human skin biopsies for EphB2 expression. The in vivo role of EphB2 in skin fibrosis was investigated by subjecting Ephb2‐knockout mice
-
“Rounding Third Base and Heading Home”: Arthritis & Rheumatology in 2024 Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-04 Daniel H. Solomon, Mariana J. Kaplan, Peter A. Nigrovic, Richard Bucala
-
Professional antigen‐presenting Tbet+CD11c+ B cells correlate with bone destruction in untreated rheumatoid arthritis Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-04 Sarah McGrath, Kristoffer Grimstad, Katrin Thorarinsdottir, Kristina Forslind, Daniel Glinatsi, Monica Leu Agelii, Alaitz Aranburu, Timothy Sundell, Charlotte A. Jonsson, Alessandro Camponeschi, Anna‐Karin Hultgård Ekwall, Andreas Tilevik, Inger Gjertsson, Inga‐Lill Mårtensson
-
Dysregulated NUB1 and neddylation enhances rheumatoid arthritis fibroblast‐like synoviocyte inflammatory responses Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-03 Sho Sendo, Camilla R. L. Machado, David L Boyle, Robert J. Benschop, Narayanan B. Perumal, Eunice Choi, Wei Wang, Gary S Firestein
-
Comment on: PD‐L1‐expressing macrophages play a protective role in the joint during arthritis Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-01 Megan Kay Wood, Taejoon Won, Daniela Čiháková
-
The extinction of primary polyarteritis nodosa: a modern science success story? Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-01 Dana Kidder, Neil Basu
-
Comment on: PD‐L1‐expressing macrophages play a protective role in the joint during arthritis Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-01 Wang‐Dong Xu, An‐Fang Huang
-
Outcomes of patients with diffuse systemic sclerosis eligible for autologous stem cell transplantation managed with conventional therapy Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-01 Kate Gregory, Dylan Hansen, Ross Penglase, Diane Apostolopoulos, Gene‐Siew Ngian, Wendy Stevens, Kathleen Morrisroe, Nava Ferdowsi, Laura Ross, Jennifer Walker, Helen Cooley, Peter Youssef, Kathleen Tymms, Lauren Host, Susanna Proudman, John Moore, Mandana Nikpour, Joanne Sahhar
ObjectiveTo determine the event‐free survival of Australian patients with diffuse systemic sclerosis (dcSSc), who meet eligibility criteria for autologous stem cell transplant (ASCT) in previously published randomised controlled trials (RCTs), but were managed without ASCT.MethodsPatients who met inclusion criteria for the ASTIS (Autologous Stem Cell Transplantation International Scleroderma)(1) and
-
Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: Results from a head‐to‐head randomized phase IIIb study Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-01 Xenofon Baraliakos, Mikkel Østergaard, Denis Poddubnyy, Désirée van der Heijde, Atul Deodhar, Pedro M. Machado, Victoria Navarro‐Compán, Kay Geert A. Hermann, Mitsumasa Kishimoto, Eun Young Lee, Lianne S. Gensler, Uta Kiltz, Marco F. Eigenmann, Patricia Pertel, Aimee Readie, Hanno B. Richards, Brian Porter, Juergen Braun
IntroductionSpinal radiographic progression is an important outcome in radiographic axial spondyloarthritis (r‐axSpA). SURPASS is the first head‐to‐head phase IIIb study comparing such changes in patients with r‐axSpA treated with secukinumab (IL‐17A inhibitor) versus adalimumab biosimilar (Sandoz adalimumab [SDZ‐ADL]; TNF inhibitor).MethodsBiologic‐naïve patients with active r‐axSpA, at high risk
-
Laser capture microscopy (LCM)‐RNAseq for topological mapping of synovial pathology during rheumatoid arthritis Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-01 Benjamin Van Espen, E. Barton Prideaux, Andrew R. Wilson, Camilla R.L. Machado, Sho Sendo, James Parker, Grégory Seumois, Cristiano Sacchetti, Anna C. Belongia, Narayanan B. Perumal, Pandurangan Vijayanand, Matthew D. Linnik, Robert J. Benschop, Wei Wang, Nunzio Bottini, Gary S. Firestein, Stephanie M. Stanford
ObjectiveRheumatoid arthritis (RA) is an autoimmune disease in which the joint lining, or synovium, becomes highly inflamed and majorly contributes to disease progression. Understanding pathogenic processes in RA synovium is critical for identifying therapeutic targets. We performed laser capture microscopy (LCM) followed by RNA sequencing (LCM‐RNAseq) to study regional transcriptomes throughout RA
-
-
-
-
-
Synovial 5‐LOX‐derived oxylipins define a lympho‐myeloid‐enriched synovium Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-21 Jessica D. Murillo‐Saich, Roxana Coras, Julio Ramirez, Estefania Quesada‐Masachs, Marta Sala‐Climent, Katharina Eschelbach, Christopher B Mahony, Raquel Celis, Aaron Armando, Oswald Quehenberger, Adam P Croft, Arthur Kavanaugh, Eric Chang, Juan D. Cañete, Abha Singh, Monica Guma
ObjectiveOxylipins are bioactive lipids derived from polyunsaturated fatty acids (PUFAs) that modulate inflammation and may remain overexpressed in refractory synovitis. In plasma, they could also be biomarkers of synovial pathology. The aim of this study is to determine if synovial oxylipins in inflamed joints correlate with plasma oxylipins and with synovial histological patterns.MethodsPatients
-
Standing on Shoulders: Interferon Research, from Viral Interference to Lupus Pathogenesis and Treatment Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-19 Mary K. Crow, Mikhail Olferiev, Kyriakos A. Kirou
The discovery of interferon in the 1950s represents much more than the identification of the first cytokine and the key mediator of anti‐viral host defense. Defining the molecular nature and complexity of the type I interferon family, as well as its inducers and molecular mechanisms of action, was the work of investigators working at the highest level and producing insights of great consequence. Current
-
The systemic score may identify life‐threatening evolution in Still's disease: data from the GIRRCS AOSD‐study group and the AIDA Network Still's Disease Registry Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-19 Piero Ruscitti, Francesco Masedu, Antonio Vitale, Valeria Caggiano, Ilenia Di Cola, Paola Cipriani, Marco Valenti, Henrique A Mayrink Giardini, Isabele Parente de Brito Antonelli, Marilia Ambiel Dagostin, Giuseppe Lopalco, Florenzo Iannone, Morrone Maria, Ibrahim A Almaghlouth, Kazi Nur Asfina, Hebatallah Hamed Ali, Francesco Ciccia, Daniela Iacono, Ilenia Pantano, Daniele Mauro, Petros P Sfikakis
-
Myeloablation followed by hematopoietic stem cell transplantation leads to long‐term normalization of systemic sclerosis molecular signatures Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-18 Nancy Wareing, Xuan Wang, Lynette Keyes‐Elstein, Ellen A. Goldmuntz, Marka A. Lyons, Peter McSweeney, Daniel E. Furst, Richard A. Nash, Leslie J. Crofford, Beverly Welch, Ashley Pinckney, Maureen D. Mayes, Keith M. Sullivan, Shervin Assassi
ObjectiveIn the randomized Scleroderma: Cyclophosphamide Or Transplantation (SCOT trial), myeloablation, followed by hematopoietic stem cell transplantation (HSCT), led to normalization of systemic sclerosis (SSc) peripheral blood gene cell (PBC) expression signature at the 26‐month visit. Herein, we examined long‐term molecular changes ensuing 54 months after randomization for individuals receiving
-
Risk of Relapse of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-14 Mats L. Junek, Peter A. Merkel, Eswari Vilayur, Ron Wald, Nader Khalidi, David Jayne, Michael Walsh
Relapses of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis are important events that can cause organ dysfunction and reduce quality of life. Understanding the effects of the initial treatments for ANCA-associated vasculitis on the subsequent risk of relapse may help guide monitoring and treatment.
-
Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐enriched Rheumatoid Arthritis Patients Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-14 Christina Charles‐Schoeman, Roy Fleischmann, Eduardo Mysler, Maria Greenwald, Steven R. Ytterberg, Gary G. Koch, Deepak L. Bhatt, Cunshan Wang, Ted R. Mikuls, All‐shine Chen, Carol A. Connell, John C. Woolcott, Sujatha Menon, Yan Chen, Kristen Lee, Zoltán Szekanecz
ObjectiveThe ORAL Surveillance trial found a dose‐dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events with tofacitinib versus tumor necrosis factor inhibitors (TNFi). We aimed to assess VTE incidence over time and explore risk factors of VTE, including disease activity, in ORAL Surveillance.MethodsPatients with rheumatoid arthritis (RA) aged ≥50 years with ≥1 additional
-
LAMP3 induces ectopic TLR7 expression in salivary gland epithelial cells and amplifies type I IFN production in Sjögren's disease Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-13 Hiroyuki Nakamura, Tsutomu Tanaka, Changyu Zheng, Sandra A. Afione, Tatsuya Atsumi, Masayuki Noguchi, Fabiola Reis Oliveira, Ana Carolina F. Motta, Fernando Chahud, Eduardo M. Rocha, Blake M. Warner, John A. Chiorini
-
Clinical Image: Nasal rim sign: A clinical manifestation of dermatomyositis Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-04 Sweta Subhadarshani, Madeline Hunt, Kerith Spicknall
The patient, a 69-year-old African American woman, presented with a three-month history of digital ulcers, Raynaud phenomenon, and occasional cough in addition to an eruption on her nose, back, and elbows. The patient denies any oral ulcers or nail changes. She also denied any photosensitivity, arthralgia, morning stiffness, muscle weakness or pain, fever, chills, weight loss, difficulty swallowing
-
Genetic Approaches to Study Rheumatic Diseases and Its Implications in Clinical Practice Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-04 Dorota Rowczenio, Ivona Aksentijevich
-
Phosphatidic Acid Promoting the Generation of Interleukin-17A Producing Double-Negative T Cells by Enhancing mTORC1 Signaling in Lupus Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-04 Wenjing Li, Xiaojun Tang, Yuanyuan Zheng, Xuefeng Xu, Nan Zhao, Betty P. Tsao, Xuebing Feng, Lingyun Sun
-
-
-
-
-
Expansion of HLA-DR Positive Peripheral Helper T and Naive B cells in Anticitrullinated Protein Antibody-Positive Individuals At Risk for Rheumatoid Arthritis Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-02-27 Hideto Takada, M. Kristen Demoruelle, Kevin D. Deane, Shohei Nakamura, Yasuhiro Katsumata, Katsunori Ikari, Jane H. Buckner, William H. Robinson, Jennifer A. Seifert, Marie L. Feser, LauraKay Moss, Jill M. Norris, Masayoshi Harigai, Elena W. Y. Hsieh, V. Michael Holers, Yuko Okamoto
-
Hyperuricemia Subtypes Classified According to Renal Uric Acid Handling Manifesting Distinct Phenotypic and Genetic Profiles in People With Gout Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-02-27 Han Qi, Mingshu Sun, Robert Terkeltaub, Tony R. Merriman, Haibing Chen, Zhiqiang Li, Aichang Ji, Xiaomei Xue, Wenyan Sun, Can Wang, Xinde Li, Yuwei He, Lingling Cui, Nicola Dalbeth, Changgui Li
Hyperuricemia can be stratified into four subtypes according to renal uric acid handling. The aim of this study was to comprehensively describe the biologic characteristics (including genetic background) of clinically defined hyperuricemia subtypes in two large geographically independent gout cohorts.
-
A diagnostic performance study of the 2023 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for patients with antiphospholipid syndrome from the Antiphospholipid Syndrome Chinese Collaborative cohort presenting with suspected antiphospholipid syndrome Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-02-25 Qingyi Lu, Yuzhou Gan, Zhongqiang Yao, Chun Li
The 2023 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) antiphospholipid syndrome (APS) classification criteria incorporate more clinical items and use weighted items with the aim of classifying APS with increased specificity.1 The new criteria has been validated in two cohorts, but none of the patients and centers are from Asian populations. To evaluate
-
Introducing the Office of Autoimmune Disease Research Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-02-25 Victoria K. Shanmugam, Janine A. Clayton
Introduction Although the exact prevalence of autoimmune diseases is unknown, estimates suggest they affect 7% to 8% of the US population.1-3 Mortality data for autoimmune diseases as a whole are incomplete due to challenges in reporting. However, a study from 2000 evaluated combined mortality data from 24 autoimmune diseases and demonstrated that, taken together, death from these conditions would
-
Changes in the Workforce Characteristics of Providers Who Care for Adult Patients With Rheumatologic and Musculoskeletal Disease in the United States Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-02-25 Melissa L. Mannion, Fenglong Xie, John D. FitzGerald, Amanda Alexander, Amy Mudano, Yujie Su, Kenneth G. Saag, Jeffrey R. Curtis
-
Association of Muscle Quality and Pain in Adults With Symptomatic Knee Osteoarthritis, Independent of Muscle Strength: Findings From a Cross-Sectional Study Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-02-25 Alisa J. Johnson, Sarah M. Barron, Jennifer A. Nichols, Yenisel Cruz-Almeida
Knee osteoarthritis (OA) is a leading cause of chronic pain in adults and shows wide interindividual variability, with peripheral and central factors contributing to the pain experience. Periarticular factors, such as muscle quality (eg, echo intensity [EI] and shear wave velocity [SWV]), may contribute to knee OA pain; however, the role of muscle quality in OA symptoms has yet to be fully established
-
Intra-Articular Mineralization on Computerized Tomography of the Knee and Risk of Cartilage Damage: The Multicenter Osteoarthritis Study Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-02-19 Jean W. Liew, Mohammed Jarraya, Ali Guermazi, John Lynch, David Felson, Michael Nevitt, Cora E. Lewis, James Torner, Frank W. Roemer, Michel D. Crema, Na Wang, Fabio Becce, Gabriela Rabasa, Tristan Pascart, Tuhina Neogi
Intra-articular (IA) mineralization may contribute to osteoarthritis (OA) structural progression. We studied the association of IA mineralization on knee computed tomography (CT) with cartilage damage worsening on knee magnetic resonance imaging (MRI), with a focus on location- and tissue-specific effects.
-
A Multilayered Post–Genome-Wide Association Study Analysis Pipeline Defines Functional Variants and Target Genes for Systemic Lupus Erythematosus Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-02-19 Mehdi Fazel-Najafabadi, Loren L. Looger, Harikrishna Reddy Rallabandi, Swapan K. Nath
Systemic lupus erythematosus (SLE), an autoimmune disease with incompletely understood etiology, has a strong genetic component. Although genome-wide association studies (GWASs) have revealed multiple SLE susceptibility loci and associated single-nucleotide polymorphisms (SNPs), the precise causal variants, target genes, cell types, tissues, and mechanisms of action remain largely unknown.
-
Effect of Intravenous Zoledronic Acid on Total Knee Replacement in Patients With Symptomatic Knee Osteoarthritis and Without Severe Joint Space Narrowing: A Prespecified Secondary Analysis of a Two-Year, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-02-18 Guoqi Cai, Laura L. Laslett, Michael Thompson, Flavia Cicuttini, Catherine Hill, Anita E. Wluka, Lyn March, Yuanyuan Wang, Petr Otahal, James D. Stoney, Benny Antony, Kathy Buttigieg, Tania Winzenberg, Graeme Jones, Dawn Aitken
-
A Novel Human Interleukin-23A Overexpressing Mouse Model of Systemic Lupus Erythematosus Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-02-15 Eleni Christodoulou-Vafeiadou, Christina Geka, Lida Iliopoulou, Lydia Ntari, Maria C. Denis, Niki Karagianni, George Kollias
-
Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-02-12 Omer Karadag, Ertugrul Cagri Bolek, Gizem Ayan, Aladdin J. Mohammad, Peter C. Grayson, Christian Pagnoux, Eduardo Martín-Nares, Sara Monti, Yoshiyuki Abe, Federico Alberici, Fatma Alibaz-Oner, David Cuthbertson, Lorenzo Dagna, Haner Direskeneli, Nader A. Khalidi, Curry Koening, Carol A. Langford, Carol A. McAlear, Paul A. Monach, Luca Moroni, Roberto Padoan, Phillip Seo, Kenneth J. Warrington, Alojzija
-
Using Two Predictive Models to Capture Two Types of Poor Outcomes in Knee Arthroplasty: A Multisite Longitudinal Cohort Study Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-02-07 Daniel L. Riddle, Levent Dumenci
-
Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis–Associated Lymphoproliferative Disorders Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-01-25 Yoshihiko Hoshida, Atsuko Tsujii, Shiro Ohshima, Yukihiko Saeki, Masato Yagita, Tomoya Miyamura, Masao Katayama, Tomonori Kawasaki, Yasushi Hiramatsu, Hisaji Oshima, Toshihiko Murayama, Shinji Higa, Kazuya Kuraoka, Fuminori Hirano, Kenji Ichikawa, Mitsutoshi Kurosawa, Hiroaki Suzuki, Noriyuki Chiba, Takao Sugiyama, Yuko Minami, Hitoshi Niino, Atsushi Ihata, Ikuo Saito, Akiko Mitsuo, Toshitaka Maejima
-
Hydroxychloroquine in Lupus Pregnancy and Risk of Preeclampsia Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-01-25 Amadeia Rector, Ivana Marić, Yashaar Chaichian, Eliza Chakravarty, Miranda Cantu, Michael H. Weisman, Gary M Shaw, Maurice L. Druzin, Julia F. Simard
Systemic lupus erythematosus (SLE) disproportionately affects women during childbearing years, and hydroxychloroquine (HCQ) is the standard first-line treatment. Preeclampsia complicates up to one-third of pregnancies in lupus patients, although reports vary by parity and multifetal gestation. We investigated whether taking HCQ early in pregnancy may reduce the risk of preeclampsia.
-
Predisposal of Interferon Regulatory Factor 1 Deficiency to Accumulate DNA Damage and Promote Osteoarthritis Development in Cartilage Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-01-25 Yongsik Cho, Hyeonkyeong Kim, Geunho Yook, Sangmin Yong, Soy Kim, Narae Lee, Yi-Jun Kim, Jin-Hee Kim, Tae Woo Kim, Moon Jong Chang, Kyoung Min Lee, Chong Bum Chang, Seung-Baik Kang, Jin-Hong Kim
-
Plasma Matrix Metalloproteinase Concentrations and Risk of Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-01-25 Brent A. Luedders, Austin M. Wheeler, Dana P. Ascherman, Joshua F. Baker, Michael J. Duryee, Yangyuna Yang, Punyasha Roul, Katherine D. Wysham, Paul Monach, Andreas Reimold, Gail S. Kerr, Gary Kunkel, Grant W. Cannon, Jill A. Poole, Geoffrey M. Thiele, Ted R. Mikuls, Bryant R. England
To evaluate the associations of plasma matrix metalloproteinases (MMPs) with prevalent and incident interstitial lung disease (ILD) in people with rheumatoid arthritis (RA).
-
CCL19-Positive Lymph Node Stromal Cells Govern the Onset of Inflammatory Arthritis via Tropomyosin Receptor Kinase Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-01-25 Fabian Schälter, Vugar Azizov, Michael Frech, Kerstin Dürholz, Eva Schmid, Anna Hendel, Ilann Sarfati, Yuichi Maeda, Maria Sokolova, Ippei Miyagawa, Kristin Focke, Kerstin Sarter, Lisa G. M. van Baarsen, Stefan Krautwald, Georg Schett, Mario M. Zaiss
The study objective was to assess the role of CCL19+ lymph node stromal cells of the joint-draining popliteal lymph node (pLN) for the development of arthritis.
-
Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-01-25 Takayuki Miyamoto, Kazushi Izawa, Sho Masui, Atsue Yamazaki, Yuichi Yamasaki, Tadashi Matsubayashi, Mayuka Shiraki, Hidenori Ohnishi, Junko Yasumura, Tomohiro Kawabe, Takako Miyamae, Tomoyo Matsubara, Naoya Arakawa, Takashi Ishige, Takumi Takizawa, Asami Shimbo, Masaki Shimizu, Naoki Kimura, Yuichi Maeda, Yuta Maruyama, Tomonari Shigemura, Junichi Furuta, Satoshi Sato, Hiroshi Tanaka, Miharu Izumikawa
-
Myositis-Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-01-25 Matthew A. Sherman, Payam Noroozi Farhadi, Katherine Pak, Edward P. Trieu, Kakali Sarkar, Ira N. Targoff, Megan L. Neely, Andrew L. Mammen, Lisa G. Rider
Myositis-associated autoantibodies (MAAs) have been associated with overlap myositis, certain disease manifestations such as interstitial lung disease (ILD), and worse prognosis in the idiopathic inflammatory myopathies. MAAs overall remain largely uncharacterized in patients with juvenile-onset myositis. Moreover, it is unknown whether the number of MAAs is associated with disease severity.
-
Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-01-25 Karen H. Costenbader, Nancy R. Cook, I-Min Lee, Jill Hahn, Joseph Walter, Vadim Bubes, Gregory Kotler, Nicole Yang, Sonia Friedman, Erik K. Alexander, JoAnn E. Manson
In the 5.3-year randomized, 2 × 2 factorial, double-blind, placebo-controlled Vitamin D and Omega-3 Trial (VITAL), vitamin D supplementation reduced autoimmune disease (AD) incidence (hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.61–0.99). Omega-3 (n-3) fatty acid supplementation showed a statistically nonsignificant reduction (HR 0.85, 95% CI 0.67–1.08). We aimed to confirm further AD cases
-
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-01-22 Stefan Siebert, Laura C. Coates, Georg Schett, Siba P. Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D. Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P. Kollmeier, Xie L. Xu, Proton Rahman, Philip J. Mease, Atul Deodhar
We assessed and compared immunologic differences and associations with clinical response to guselkumab, a fully human interleukin (IL)–23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) who were biologic-naive or had inadequate response to tumor necrosis factor inhibitors (TNFi-IR).
-
Choosing to End African American Health Disparities in SLE Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-01-16 Matthew H. Liang, Edward R. Lew, Patricia A. Fraser, Cindy Flower, Edward H. Hennis, Sang-Cheol Bae, Anselm Hennis, Mohammed Tikly, W. Neal Roberts
Systemic Lupus erythematosus (SLE) is 3 times more common and its’ manifestations more severe in African American (AA) women compared to women of other races. It is not clear whether this is due to genetic differences or factors related to the physical or social environments, differences in health care or a combination of these factors. Health disparities in SLE between AAs and persons of other races
-
Calprotectin Impairs Platelet Survival in Patients With Primary Antiphospholipid Syndrome Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-01-16 Claire K. Hoy, Somanathapura K. NaveenKumar, Sherwin A. Navaz, Kavya Sugur, Srilakshmi Yalavarthi, Cyrus Sarosh, Tristin Smith, Katarina Kmetova, Emily Chong, Noah F. Peters, Christine E. Rysenga, Gary L. Norman, Gabriel Figueroa-Parra, Dava Nelson, Jennifer Girard, Asra Z. Ahmed, Jordan K. Schaefer, Johann E. Gudjonsson, J. Michelle Kahlenberg, Jacqueline A. Madison, Jason S. Knight, Cynthia S. Crowson
-
VEXAS-Defining UBA1 Somatic Variants in 245,368 Diverse Individuals in the NIH All Of Us Cohort Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-01-15 Robert W. Corty, James Brogan, Kevin Byram, Jason Springer, Peter C. Grayson, Alexander G. Bick
-
Rheum at the Table for Everyone: A Call to Expand Rheumatology Knowledge for Primary Care Providers Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-01-14 Mary E. Margaretten, Jinoos Yazdany, Jennifer Mandal
Introduction In the past 25 years, there has been an explosion of rheumatology knowledge and treatment options simultaneously occurring with a decreased supply of rheumatologists to provide specialized care for patients with complex autoimmune diseases. Reasons for the workforce shortage include an aging population with increased prevalence of arthritis, more part-time clinicians, and increasing retirement